MICHELUCCI, ELENA
 Distribuzione geografica
Continente #
AS - Asia 1.218
NA - Nord America 793
EU - Europa 314
SA - Sud America 161
Continente sconosciuto - Info sul continente non disponibili 85
AF - Africa 15
OC - Oceania 2
Totale 2.588
Nazione #
US - Stati Uniti d'America 762
SG - Singapore 475
CN - Cina 297
HK - Hong Kong 154
BR - Brasile 138
IT - Italia 123
VN - Vietnam 115
FR - Francia 67
KR - Corea 59
FI - Finlandia 31
NL - Olanda 29
IN - India 25
JP - Giappone 25
BD - Bangladesh 17
DE - Germania 15
GB - Regno Unito 14
CA - Canada 12
MX - Messico 11
IL - Israele 9
TR - Turchia 8
ES - Italia 7
IQ - Iraq 7
AR - Argentina 6
EC - Ecuador 6
ID - Indonesia 5
IE - Irlanda 5
PH - Filippine 4
PK - Pakistan 4
RU - Federazione Russa 4
AT - Austria 3
CL - Cile 3
CO - Colombia 3
EG - Egitto 3
MA - Marocco 3
NP - Nepal 3
UZ - Uzbekistan 3
AU - Australia 2
BG - Bulgaria 2
CH - Svizzera 2
JM - Giamaica 2
KE - Kenya 2
PE - Perù 2
SA - Arabia Saudita 2
TN - Tunisia 2
ZA - Sudafrica 2
AZ - Azerbaigian 1
BE - Belgio 1
BO - Bolivia 1
CG - Congo 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
KH - Cambogia 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MV - Maldive 1
NI - Nicaragua 1
PL - Polonia 1
RS - Serbia 1
SE - Svezia 1
SI - Slovenia 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
UA - Ucraina 1
UY - Uruguay 1
VE - Venezuela 1
ZW - Zimbabwe 1
Totale 2.503
Città #
Singapore 283
Santa Clara 248
Hong Kong 150
Hefei 136
San Jose 93
Ashburn 76
Seoul 57
Lauterbourg 55
Dallas 49
Los Angeles 49
Beijing 46
Ho Chi Minh City 41
Hanoi 28
Pisa 20
Modena 15
Tokyo 14
São Paulo 13
Helsinki 12
New York 12
Lappeenranta 11
Minamishinagawa 9
Cascina 8
Turku 8
Bengaluru 7
Boston 7
Livorno 7
Rio de Janeiro 7
Buffalo 6
Denver 6
Indianapolis 6
Milan 6
Orem 6
Atlanta 5
Dublin 5
Florence 5
Frankfurt am Main 5
Haiphong 5
Montreal 5
Munich 5
Phoenix 5
Bologna 4
Campinas 4
Charlotte 4
City of London 4
Da Nang 4
Dhaka 4
London 4
Shenzhen 4
Washington 4
Belo Horizonte 3
Biên Hòa 3
Bắc Ninh 3
Curitiba 3
Hangzhou 3
Hyderabad 3
Kolkata 3
Mexico City 3
Mosul 3
Mumbai 3
Nuremberg 3
Osasco 3
Piscataway 3
Rome 3
San Francisco 3
Tashkent 3
Thái Nguyên 3
Ankara 2
Belém 2
Betim 2
Brasília 2
Bảo Lộc 2
Charleston 2
Chicago 2
Cuenca 2
Dundee 2
Fortaleza 2
Goiânia 2
Guarujá 2
Guayaquil 2
Hải Dương 2
Kathmandu 2
Lages 2
Lauro de Freitas 2
Londrina 2
Madrid 2
Manchester 2
Marseille 2
Nairobi 2
Naples 2
Paris 2
Pavia 2
Querétaro 2
Quận Sáu 2
Rouen 2
Sanford 2
Scottsdale 2
Surat 2
São Bernardo do Campo 2
Tampa 2
Tunis 2
Totale 1.686
Nome #
The Clinical Utility of the Saliva Proteome in Rare Diseases: A Pilot Study for Biomarker Discovery in Primary Sclerosing Cholangitis 114
Plasma lipidomics and coronary plaque changes: a substudy of the SMARTool clinical trial 99
Homotypic targeting and drug delivery in glioblastoma cells through cell membrane-coated boron nitride nanotubes 96
Proteomic Modulation in TGF-b-Treated Cholangiocytes Induced by Curcumin Nanoparticles 80
Exploring metal complexes-protein/peptide interactions by high resolution mass spectrometry 79
A specific plasma lipid signature associated with high triglycerides and low HDL cholesterol identifies residual CAD risk in patients with chronic coronary syndrome 77
Targeting autophagy impairment improves the phenotype of a novel CLN8 zebrafish model 74
Predictive added value of selected plasma lipids to a re-estimated minimal risk tool 74
Ceramides as mediators of oxidative stress and inflammation in cardiometabolic disease 73
Lipidomic analysis to assess the correlation between ceramides, stress hyperglycemia, and HbA1c in acute myocardial infarction 66
A targeted LC-MS/MS analysis of circulatory lipid profile to highlight biomarkers for patient stratification according to coronary artery disease severity 62
Molecular characterization of plasma HDL, LDL, and VLDL lipids cargos from atherosclerotic patients with advanced carotid lesions: a preliminary report 58
Biological effects of Transforming Growth Factor Beta in human cholangiocytes 57
Ceramides and Cardiovascular Risk Factors, Inflammatory Parameters and Left Ventricular Function in AMI Patients 56
Salivary proteomics markers for preclinical Sjögren's Syndrome: a pilot study 56
Integrative human and murine multi-omics: Highlighting shared biomarkers in the neuronal ceroid lipofuscinoses 55
Relazione 3 (finale): Relazione finale protocollata e stesura di un protocollo analitico definitivo con gli step raggiunti su metodo per analisi quantitativa HPLC-QTRAP 54
Lipid biomarkers in statin users with coronary artery disease annotated by coronary computed tomography angiography 54
Novel platinum(ii) compounds with O,S bidentate ligands: Synthesis, characterization, antiproliferative properties and biomolecular interactions 52
A targeted LC-MS/MS analysis of the human plasma lipid profile to highlight novel markers of coronary artery disease severity 52
Bottom-up mass spectrometry proteomics strategies for the identification of metallodrug binding sites on proteins: the search for a general protocol to assess adduct stability 51
Comparative proteomics profiling through DIA-SWATH-MS analysis in WT vs PPT1 KO "neuron-like" human cell lines as CLN1 model 51
Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: Biological and pharmacological implications 50
Candidate biomarkers for mosquito age-grading identified by label-free quantitative analysis of protein expression in Aedes albopictus females 48
Proteomic analyses and integrative omics approach to highlight the common molecular signatures for different NCL forms 47
A common plasma lipidomics signature of cardiometabolic and coronary risk in statin users 44
Cytotoxic profile and peculiar reactivity with biomolecules of a novel "rule-breaker" iodidoplatinum(II) complex 43
Inorganic nanoparticles as potential regulators of immune response in dendritic cells 37
PtI2(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features 35
Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments 33
Interactions of selected gold(iii) complexes with DNA G quadruplexes 31
Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The comparison with auranofin 31
Mass spectrometry and metallomics: stability and binding site location in the Cyt c-CDDP model system 31
Mass Spectrometry and Metallomics: binding site location in the Cyt c-CDDP model system 30
Interactions between anticancer trans -platinum compounds and proteins: Crystal structures and esi-ms spectra of two protein adducts of trans -(dimethylamino)(methylamino)dichloridoplatinum(II) 29
Insights on the mechanism of thioredoxin reductase inhibition by Gold N-heterocyclic carbene compounds using the synthetic linear Selenocysteine containing C-terminal peptide hTrxR(488-499): An ESI-MS investigation 29
Synthesis and preliminary biological characterization of new semisynthetic derivatives of ramoplanin 28
Bottom-up mass spectrometry proteomics strategies for the identification of metallodrug binding sites on proteins: the search for a general protocol to assess adduct stability 28
Direct coupling of FFE protein separation and MALDI-TOF analysis 27
Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles 27
Elucidating the reactivity of Pt(II) complexes with (O,S) bidentate ligands towards DNA model systems 26
Ramoplanin derivatives possessing antibacterial activity 26
Cooperative interactions between odorant-binding proteins of Anopheles gambiae 26
Correction: Reactions of metallodrugs with proteins: Selective binding of phosphane-based platinum(ii) dichlorides to horse heart cytochrome: C probed by ESI MS coupled to enzymatic cleavage (Metallomics (2011) 3 (987-990) DOI: 10.1039/c1mt00069a) 25
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(ii) compounds with sulfur and phosphorus donors 25
Top-down sequencing of Apis dorsata apamin by MALDI-TOF MS and evidence of its inactivity against microorganisms 25
Cancer associated fibroblasts transfer lipids and proteins to cancer cells through cargo vesicles supporting tumor growth 24
fac-{Ru(CO)3}2+ selectively targets the histidine residues of the beta-amyloid peptide 1-28. Implications for new Alzheimer's disease treatments based on ruthenium complexes 24
Exploring metallodrug-protein interactions by mass spectrometry: Comparisons between platinum coordination complexes and an organometallic ruthenium compound 23
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand 23
Reactions of cytotoxic metallodrugs with lysozyme in pure DMSO explored through UV-Vis absorption spectroscopy and ESI MS 22
Differential expression of odorant-binding proteins in the mandibular glands of the honey bee according to caste and age 22
Exploring the interactions between phosphane-based platinum(II) dichlorides and cytochrome c by electrospray ionization high resolution mass spectrometry 22
Gold(III) complexes with hydroxyquinoline, aminoquinoline and quinoline ligands: Synthesis, cytotoxicity, DNA and protein binding studies 21
Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles 21
Protein metalation by metal-based drugs: Reactions of cytotoxic gold compounds with cytochrome c and lysozyme 21
Exploring the interactions of a "rule-breaker" iodo-platinum(II) complex with cytochrome c by mass spectrometry 21
[Au2(phen2Me)2(µ-O)2](PF6)2, a novel dinuclear gold(III) complex showing excellent antiproliferative properties 20
Odorant-binding proteins and chemosensory proteins in pheromone detection and release in the silkmoth Bombyx mori 18
Interactions of the organogold(III) compound Aubipyc with the copper chaperone Atox1: A joint mass spectrometry and circular dichroism investigation 16
Reactivity and biological properties of a series of cytotoxic PtI2(amine)2 complexes, either cis or trans configured 15
Miglustat does not impact clinical progression in patients with spastic paraplegia type 11 4
Totale 2.588
Categoria #
all - tutte 9.347
article - articoli 7.238
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.585


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202493 0 0 0 0 0 0 0 0 11 64 17 1
2024/2025950 15 7 74 37 261 15 29 52 31 36 245 148
2025/20261.484 91 158 111 220 270 47 269 47 69 115 53 34
2026/202761 61 0 0 0 0 0 0 0 0 0 0 0
Totale 2.588